|Bid||364.96 x 1000|
|Ask||365.04 x 800|
|Day's range||344.50 - 365.52|
|52-week range||341.03 - 555.77|
|Beta (5Y monthly)||0.89|
|PE ratio (TTM)||59.74|
|Earnings date||10 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||429.94|
Genomic sequencing leader Illumina (NASDAQ: ILMN) recently provided guidance for 2022 and revealed some of its plans for the year. In this Motley Fool Live video, recorded on Jan. 12, Fool contributors Keith Speights and Brian Orelli discuss the outlook for Illumina going forward. Keith Speights: Hey, there's a company that you and I haven't talked about very much, at least, I'm going to say at least over the last seven or eight months and maybe longer than that.
In this Motley Fool Live video recorded on Jan. 12, 2022, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not the two companies are rising stars in healthcare. Keith Speights: Illumina, which we've talked about, and Beam Therapeutics, she says, "Are they rising stars, and what about other CRISPR stocks?" Are Illumina and Beam rising stars, Brian?
Investors are optimistic about Illumina (ILMN) owing to its strength in international markets and notable strategic partnerships.